Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorAnderson, Heather
dc.contributor.authorJames, R
dc.contributor.authorDavenport, P
dc.contributor.authorCraig, P
dc.date.accessioned2010-07-21T10:13:49Z
dc.date.available2010-07-21T10:13:49Z
dc.date.issued1986-06-01
dc.identifier.citationTreatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation. 1986, 57 (11):2103-7 Canceren
dc.identifier.issn0008-543X
dc.identifier.pmid3697910
dc.identifier.doi10.1002/1097-0142(19860601)57:11<2103::AID-CNCR2820571102>3.0.CO;2-G
dc.identifier.urihttp://hdl.handle.net/10541/108029
dc.description.abstractForty-three patients with widely metastatic melanoma were studied. Visceral metastases were present in 79% of the patient group, including five patients with brain metastases. No patients were excluded because of "early death," etc., from analysis. All 43 patients received 24-hour DTIC infusions. Dosages for individual patients ranged from 350 mg/M2 to 2.5 g/M2, a maximum of 6 courses being given. A total of 155 courses was administered. Hemibody irradiation (HBI) was delivered after 1 or 3 courses of DTIC to the area of maximum disease in 23 patients. Fourteen of the 43 patients responded to DTIC chemotherapy (with one complete response), a response rate of 33%. Seven of the chemotherapy responders also responded in other sites to subsequent HBI, a response rate of 30% (7/23). No patient responded to HBI and not to DTIC. Median survival was 4 months (range, 1-15), and nine patients are still alive at 3 to 15 months. Toxicity was generally mild, although there was one possible treatment-related death. Further exploration of DTIC infusion chemotherapy and HBI would be of interest.
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subjectSkin Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCombined Modality Therapy
dc.subject.meshDacarbazine
dc.subject.meshEvaluation Studies as Topic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshRadiotherapy Dosage
dc.subject.meshSkin Neoplasms
dc.subject.meshTime Factors
dc.titleTreatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, England.en
dc.identifier.journalCanceren
html.description.abstractForty-three patients with widely metastatic melanoma were studied. Visceral metastases were present in 79% of the patient group, including five patients with brain metastases. No patients were excluded because of "early death," etc., from analysis. All 43 patients received 24-hour DTIC infusions. Dosages for individual patients ranged from 350 mg/M2 to 2.5 g/M2, a maximum of 6 courses being given. A total of 155 courses was administered. Hemibody irradiation (HBI) was delivered after 1 or 3 courses of DTIC to the area of maximum disease in 23 patients. Fourteen of the 43 patients responded to DTIC chemotherapy (with one complete response), a response rate of 33%. Seven of the chemotherapy responders also responded in other sites to subsequent HBI, a response rate of 30% (7/23). No patient responded to HBI and not to DTIC. Median survival was 4 months (range, 1-15), and nine patients are still alive at 3 to 15 months. Toxicity was generally mild, although there was one possible treatment-related death. Further exploration of DTIC infusion chemotherapy and HBI would be of interest.


This item appears in the following Collection(s)

Show simple item record